Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid
T H
TH
Department of Medicine, University of Kentucky, Lexington.
Lucas
B A
BA
Thompson
J S
JS
Munch
L C
LC
Brown
S
S
Kryscio
R
R
Prebeck
R
R
VanHoy
M A
MA
Jezek
D
D
D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000150:complications; D004311:Double-Blind Method; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D007958:Leukocyte Count; D016853:Muromonab-CD3; D011446:Prospective Studies; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell